$368 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 43 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 76.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMMU | Sell | IMMUNOMEDICS INC | $43,493,000 | +125.2% | 511,500 | -6.1% | 11.81% | +111.6% |
| KURA | Buy | KURA ONCOLOGY INC | $29,813,000 | +109.6% | 973,000 | +11.5% | 8.10% | +97.0% |
| XBI | New | SPDR SER TRput | $27,858,000 | – | 250,000 | +100.0% | 7.57% | – |
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $22,912,000 | +76.2% | 1,545,000 | +54.5% | 6.22% | +65.7% |
| SAGE | New | SAGE THERAPEUTICS INC | $13,752,000 | – | 225,000 | +100.0% | 3.74% | – |
| CMPS | New | COMPASS PATHWAYS PLCsponsored ads | $13,611,000 | – | 390,000 | +100.0% | 3.70% | – |
| LRMR | Buy | LARIMAR THERAPEUTICS INC | $12,591,000 | +22.6% | 830,000 | +0.8% | 3.42% | +15.2% |
| MRSN | Buy | MERSANA THERAPEUTICS INC | $12,429,000 | -16.0% | 667,500 | +5.5% | 3.38% | -21.1% |
| ALDX | Buy | ALDEYRA THERAPEUTICS INC | $12,202,000 | +228.8% | 1,646,700 | +85.0% | 3.31% | +209.1% |
| New | TRILLIUM THERAPEUTICS INC | $12,121,000 | – | 853,000 | +100.0% | 3.29% | – | |
| ETNB | New | 89BIO INC | $10,713,000 | – | 417,500 | +100.0% | 2.91% | – |
| RLMD | Buy | RELMADA THERAPEUTICS INC | $10,421,000 | -0.7% | 277,000 | +18.1% | 2.83% | -6.7% |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $10,370,000 | -36.0% | 315,000 | -46.6% | 2.82% | -39.8% |
| ALT | Buy | ALTIMMUNE INC | $9,082,000 | +57.8% | 688,000 | +28.0% | 2.47% | +48.3% |
| IMVT | Sell | IMMUNOVANT INC | $8,798,000 | +3.2% | 250,000 | -28.6% | 2.39% | -3.0% |
| CYTK | New | CYTOKINETICS INC | $7,740,000 | – | 357,500 | +100.0% | 2.10% | – |
| RAPT | New | RAPT THERAPEUTICS INC | $7,728,000 | – | 240,000 | +100.0% | 2.10% | – |
| LSACU | LIFESCI ACQUISITION CORPunit 03/31/2025 | $7,616,000 | +23.6% | 560,000 | 0.0% | 2.07% | +16.2% | |
| SURF | Buy | SURFACE ONCOLOGY INC | $7,507,000 | +408.6% | 1,088,000 | +383.6% | 2.04% | +378.6% |
| ATHA | New | ATHIRA PHARMA INC | $6,692,000 | – | 362,500 | +100.0% | 1.82% | – |
| RNA | Buy | AVIDITY BIOSCIENCES INC | $6,615,000 | +99.2% | 235,000 | +100.0% | 1.80% | +87.1% |
| CBIO | CATALYST BIOSCIENCES INC | $6,441,000 | -26.7% | 1,497,900 | 0.0% | 1.75% | -31.2% | |
| SELB | SELECTA BIOSCIENCES INC | $5,863,000 | -12.7% | 2,364,204 | 0.0% | 1.59% | -17.9% | |
| CBAY | New | CYMABAY THERAPEUTICS INC | $5,539,000 | – | 765,000 | +100.0% | 1.50% | – |
| APLS | Sell | APELLIS PHARMACEUTICALS INC | $5,040,000 | -18.8% | 167,054 | -12.1% | 1.37% | -23.6% |
| ISEE | Buy | IVERIC BIO INC | $4,526,000 | +29.1% | 802,500 | +16.7% | 1.23% | +21.3% |
| ARWR | Buy | ARROWHEAD PHARMACEUTICALS IN | $4,371,000 | +68.7% | 101,500 | +69.2% | 1.19% | +58.5% |
| CRDF | Sell | CARDIFF ONCOLOGY INC | $4,341,000 | +112.6% | 305,900 | -24.9% | 1.18% | +99.8% |
| HSAQ | New | HEALTH SCIENCES ACQ CORP 2 | $4,318,000 | – | 392,500 | +100.0% | 1.17% | – |
| SNDX | SYNDAX PHARMACEUTICALS INC | $3,553,000 | -0.4% | 240,744 | 0.0% | 0.96% | -6.4% | |
| AVDL | Sell | AVADEL PHARMACEUTICALS PLCsponsored adr | $3,554,000 | -74.9% | 705,218 | -59.8% | 0.96% | -76.4% |
| PANAU | New | PANACEA ACQUISITION CORPunit 99/99/9999 | $3,360,000 | – | 280,000 | +100.0% | 0.91% | – |
| ANNX | New | ANNEXON INC | $3,325,000 | – | 110,000 | +100.0% | 0.90% | – |
| XENE | Sell | XENON PHARMACEUTICALS INC | $3,321,000 | -48.8% | 300,000 | -42.0% | 0.90% | -51.9% |
| FULC | New | FULCRUM THERAPEUTICS INC | $3,025,000 | – | 381,500 | +100.0% | 0.82% | – |
| CNCE | New | CONCERT PHARMACEUTICALS INC | $2,946,000 | – | 300,000 | +100.0% | 0.80% | – |
| VSTM | Sell | VERASTEM INC | $2,904,000 | -36.3% | 2,400,000 | -9.4% | 0.79% | -40.1% |
| BCRX | Sell | BIOCRYST PHARMACEUTICALS | $2,267,000 | -75.0% | 660,000 | -65.3% | 0.62% | -76.5% |
| AXSM | Sell | AXSOME THERAPEUTICS INC | $1,603,000 | -78.4% | 22,500 | -75.0% | 0.44% | -79.7% |
| KRTX | Sell | KARUNA THERAPEUTICS INC | $1,044,000 | -88.0% | 13,500 | -82.7% | 0.28% | -88.7% |
| UMRX | New | UNUM THERAPEUTICS INC | $959,000 | – | 410,000 | +100.0% | 0.26% | – |
| CLSD | New | CLEARSIDE BIOMEDICAL INC | $947,000 | – | 615,000 | +100.0% | 0.26% | – |
| WVE | WAVE LIFE SCIENCES LTD | $913,000 | -18.4% | 107,500 | 0.0% | 0.25% | -23.2% | |
| AKUS | Exit | AKOUOS INC | $0 | – | -22,200 | -100.0% | -0.14% | – |
| STSA | Exit | SATSUMA PHARMACEUTICALS INC | $0 | – | -35,000 | -100.0% | -0.29% | – |
| GBIO | Exit | GENERATION BIO CO | $0 | – | -100,000 | -100.0% | -0.61% | – |
| FUSN | Exit | FUSION PHARMACEUTICALS INC | $0 | – | -135,000 | -100.0% | -0.68% | – |
| RETA | Exit | REATA PHARMACEUTICALS INCcl a | $0 | – | -15,300 | -100.0% | -0.69% | – |
| QURE | Exit | UNIQURE NV | $0 | – | -60,000 | -100.0% | -0.78% | – |
| EIGR | Exit | EIGER BIOPHARMACEUTICALS INC | $0 | – | -292,500 | -100.0% | -0.81% | – |
| AGEN | Exit | AGENUS INC | $0 | – | -932,500 | -100.0% | -1.06% | – |
| ARVN | Exit | ARVINAS INC | $0 | – | -123,000 | -100.0% | -1.19% | – |
| DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -170,000 | -100.0% | -1.25% | – |
| VIR | Exit | VIR BIOTECHNOLOGY INC | $0 | – | -127,000 | -100.0% | -1.50% | – |
| KDMN | Exit | KADMON HLDGS INC | $0 | – | -1,280,000 | -100.0% | -1.89% | – |
| APLT | Exit | APPLIED THERAPEUTICS INC | $0 | – | -182,000 | -100.0% | -1.90% | – |
| MRUS | Exit | MERUS N V | $0 | – | -460,000 | -100.0% | -2.14% | – |
| BLU | Exit | BELLUS HEALTH INC NEW | $0 | – | -765,000 | -100.0% | -2.27% | – |
| ASND | Exit | ASCENDIS PHARMA A Ssponsored adr | $0 | – | -55,500 | -100.0% | -2.37% | – |
| ADAP | Exit | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $0 | – | -1,165,000 | -100.0% | -3.37% | – |
| BTAI | Exit | BIOXCEL THERAPEUTICS INC | $0 | – | -340,500 | -100.0% | -5.22% | – |
| ADVM | Exit | ADVERUM BIOTECHNOLOGIES INC | $0 | – | -1,746,500 | -100.0% | -10.54% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.